ProfoundBio: ProfoundBio Announces Presentation on Novel, Proprietary Linker-Drug Technology to Enable Antibody-Drug Conjugates (ADCs) with an Expanded Therapeutic Window at the AACR-NCI-EORTC International Co...
WOODINVILLE, Wash. and SUZHOU, China, Oct. 7, 2021 /PRNewswire/ -- ProfoundBio announces that preclinical data from its novel, proprietary ADC tec...
Read full article »
Chairman & CEO
Baiteng Zhao
ProfoundBio is a China-based biotechnology company that develops and commercializes T-cell therapeutics for the treatment of cancer.
Read more